SCHEMBL3711282

SCHEMBL3711282

COc1ccc2c(c1)/C(=C\c1ccc3c(-c4cnc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.49
AURKB Q96GD4 6/20 0.49
PLK4 O00444 6/20 0.49
KDR P35968 5/20 0.49
PAK1 Q13153 1/20 0.44
RET P07949 5/20 0.43
LRRK2 Q5S007 5/20 0.43
TLK2 Q86UE8 3/20 0.43
CDK1 P06493 2/20 0.43
CDK2 P24941 2/20 0.43
MAPK1 P28482 2/20 0.43
GSK3A P49840 2/20 0.43
GSK3B P49841 2/20 0.43
CDK7 P50613 2/20 0.43
CDK9 P50750 2/20 0.43
CDK5 Q00535 2/20 0.43
LCK P06239 2/20 0.43
CHEK1 O14757 1/20 0.43
AURKA O14965 1/20 0.43
PDPK1 O15530 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3711285 1.00 FLT3 (0.49) FLT3AURKBPLK4KDRPAK1
SCHEMBL585823 0.91 PLK4 (0.59) FLT3AURKBPLK4KDRRET
SCHEMBL589513 0.91 PLK4 (0.59) FLT3AURKBPLK4KDRRET
SCHEMBL2542893 0.91 PLK4 (0.59) FLT3AURKBPLK4KDRRET
SCHEMBL6532066 0.91 ABL1 (0.46) FLT3AURKBPLK4KDRPAK1
SCHEMBL15849068 0.91 ABL1 (0.46) FLT3AURKBPLK4KDRPAK1
SCHEMBL6532074 0.91 ABL1 (0.46) FLT3AURKBPLK4KDRPAK1
SCHEMBL12795424 0.89 PLK4 (0.42) FLT3AURKBPLK4KDRRET
SCHEMBL3722911 0.84 FLT3 (0.60) FLT3AURKBPLK4KDRPAK1
SCHEMBL3722910 0.84 FLT3 (0.60) FLT3AURKBPLK4KDRPAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed
EP-2235004-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER University Health Network (CA) 2010-10-06 EP disclosed
WO-2009079767-A9 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-10-01 WO disclosed
WO-2009079767-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 FLT3 221/4885AURKB 40/4885PLK4 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.